The concluding paragraph provides a very clear summary of findings (2018). Essentially, they say, to prove consistency/accuracy of this type of test, refinement of biomarker panel and associated algorithm are required. Following this, testing in a 'real world' setting is needed, with all participants ultimately having a colonoscopy.
This is exactly what Rhythm have done!
Their panel of 5 bio markers and algorithm is the science coming from CSIRO, 12 years in the making. Then Rhythm's clinical trial, completed in 2022, is a 'Prospective Cross Sectional' study which means it follows a certain population of patients over a duration of time = real world. 603 patients in the study had a definitive Colostat test and colonoscopy (gold standard).
As we know, results of Rhythm's clinical trial were 91% specificity and 81.3% Sensitivity compared to colonoscopy. Excellent!
RHY Price at posting:
49.0¢ Sentiment: Buy Disclosure: Held
